Reaction

Capillary Leak Syndrome reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,026 reports · 97 co-occurring drugs

As of the last recalculation, Capillary Leak Syndrome appears in 2,026 FAERS reports alongside 97 co-occurring drug terms. The strongest observed disproportionality signal is GEMCITABINE HYDROCHLORIDE (PRR 36.3).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Gemcitabine Hydrochloride	172	36.3	36.4
Gemcitabine	117	32.3	32.4
Busulfan	46	30.7	30.8
Anti-Thymocyte Globulin (Rabbit)	22	28.3	28.4
Fludarabine Phosphate	101	27.7	27.8
Thiotepa	25	27.2	27.3
Blinatumomab	24	23.9	24.0
Cytarabine	111	20.0	20.1
Amphotericin B	24	19.9	19.9
Filgrastim	69	19.5	19.5
Micafungin Sodium	14	17.1	17.1
Basiliximab	18	15.9	15.9
Docetaxel Anhydrous	96	15.3	15.3
Docetaxel	96	15.3	15.3
Melphalan	33	15.1	15.2
Melphalan Hydrochloride	36	15.0	15.0
Bosutinib	13	15.0	15.0
Voriconazole Injection	30	14.4	14.4
Posaconazole	22	14.1	14.1
Cyclophosphamide Injection, Solution	203	13.0	13.0
Cyclophosphamide	203	13.0	13.0
Cyclophosphamide For Injection	203	13.0	13.0
Granisetron Hydrochloride	13	12.9	12.9
Voriconazole	36	12.4	12.4
Cefepime	17	12.3	12.3
Bleomycin Sulfate	12	12.0	12.0
Ursosiol	22	11.7	11.8
Paclitaxel	107	11.7	11.7
Posaconazole Delayed-Release	12	11.3	11.3
Ursodiol	23	11.0	11.0
Cefepime Hydrochloride	17	10.9	10.9
Paclitaxel (Aibumin-Bound)	84	10.9	10.9
Etoposide	75	10.8	10.9
Theophylline	12	10.8	10.8
Aprepitant	19	10.7	10.7
Meropenem	31	10.1	10.1
Norepinephrine Bitartrate	14	10.1	10.1
Theophylline Anhydrous	12	10.0	10.0
Ampicillin	8	10.0	10.0
Ampicillin Sodium	8	10.0	10.0
Granisetron	10	9.8	9.8
Piperacillin Sodium,Tazobactam Sodium	25	9.8	9.8
Piperacillin And Tazobactam	12	9.7	9.7
Norepinephrine	10	9.7	9.7
Piperacillin Sodium And Tazobactam Sodium	18	9.5	9.5
Terazosin Hydrochloride	8	9.3	9.3
Ipilimumab	37	9.0	9.0
Ganciclovir Sodium	9	8.8	8.8
Mesna Injection	7	8.7	8.7
Gentamicin	11	8.7	8.7
Mesna	7	8.6	8.6
Valganciclovir Hydrochloride Powder,	10	8.5	8.5
Pegaspargase	10	8.4	8.4
Pertuzumab	22	8.4	8.4
Vancomycin	45	8.2	8.2
Vincristine Sulfate	23	8.1	8.2
Ganciclovir	8	8.1	8.1
Pemetrexed Disodium	29	7.9	7.9
Cyclosporine	82	7.8	7.9
Valganciclovir	14	7.7	7.7
Valganciclovir Hydrochloride	14	7.7	7.7
Vancomycin Hydrochloride	48	7.6	7.6
Axitinib	14	7.4	7.4
Trastuzumab	48	7.3	7.3
Gentamicin Sulfate	11	7.2	7.2
Nivolumab	63	6.9	6.9
Cisplatin	51	6.9	6.9
Bendamustine Hcl	10	6.7	6.7
Atovaquone	5	6.4	6.4
Pembrolizumab	63	6.3	6.3
Carboplatin	75	6.3	6.3
Azacitidine For	11	6.2	6.2
Ifosfamide	12	5.8	5.8
Doxorubicin	49	5.8	5.8
Azacitidine	16	5.6	5.6
Pemetrexed	11	5.3	5.3
Doxorubicin Hydrochloride	16	5.1	5.1
Bortezomib	43	5.0	5.0
Brentuximab Vedotin	5	5.0	5.0
Sorafenib	10	5.0	5.0
Bevacizumab	56	4.7	4.8
Dasatinib	17	4.7	4.7
Fluorouracil Cream, 0.5%	34	4.6	4.6
Dapagliflozin	14	4.6	4.6
Fluorouracil	34	4.6	4.6
Fosaprepitant Dimeglumine	6	4.5	4.5
Pegfilgrastim	42	4.4	4.4
Obinutuzumab	7	4.4	4.4
Axicabtagene Ciloleucel	4	4.2	4.2
Oxaliplatin	28	3.9	3.9
Atezolizumab	14	3.7	3.7
Bendamustine Hydrochloride	4	3.4	3.4
Temozolomide	7	3.4	3.4
Daptomycin	3	3.3	3.3
Venetoclax	19	3.2	3.2
Cannabidiol	6	2.6	2.6
Remdesivir	3	2.3	2.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.